US FDA approves Evolus' anti-wrinkle gels (updated)

Evolus

13/02/2025 19:02

(Adds details on the products in paragraphs 2 to 4)
       Feb 13 (Reuters) - Evolus  EOLS.O  said on Thursday the
U.S. drug regulator has approved its two new anti-wrinkle gels,
expanding the company's product portfolio beyond its cosmetic
injection Jeuveau.
    The two dermal fillers, Evolysse Form and Evolysse Smooth,
contain hyaluronic acid and can improve the appearance of the
face by restoring volume.
    The U.S. Food and Drug Administration's approval was based
on a head-to-head study, where both the injectable gels met the
main goal of non-inferiority when compared to Switzerland-based
Galderma's  GALD.S  Restylane-L.
    Evolus plans to launch the products in the U.S. in the
second quarter of 2025.

 (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi
Majumdar)
 ((Christy.Santhosh@thomsonreuters.com))